Vermont Immunobioloigy/ Infectious Diseases Center

本申请提出了佛蒙特大学（UVM）佛蒙特免疫学和传染病中心（VCIID）的II期COBRE延续。在第一阶段COBRE期间，我们创建了一个多学科的科学家和临床医生小组，在微生物发病机制和感染的免疫反应方面进行合作研究。第一阶段的重点是实现科学卓越，同时在充满活力和严谨的气氛中建立一个研究人员的临界质量。其中一个重要组成部分是5个原始的初级教师的指导，他们都获得了校外资助，有许多出版物和奖项，5个中有4个得到了提升。在第一阶段的最后两年，我们还招募了5名初级教师。这5个新教师中已经有4个获得了一些校外资金。此外，VCIID-COBRE还为基因组技术/生物信息学、蛋白质组学、外部专家系列研讨会、每周研究进展论坛、务虚会、试点项目资助以及科学问题研讨会、赠款撰写和职业发展提供了支持。作为这些计划的结果，VCIID在第一阶段从9个创始教师成长为4个学院8个部门的21名教师，有213篇出版物（49篇来自初级教师），47，694，003美元的资金，没有COBRE（8，818，374美元来自初级教师），并被UVM医学院认可为五个卓越中心之一。 在第二阶段，我们将继续上述几个成功的计划，但修改他们对指导教师走向成为一个高度互动的群体在一个成熟的中心与合作赠款和可持续性。新的5名初级教师将继续他们的项目1-4年。我们招募了两名高级教师来填补我们知识库中的空白，一个是粘膜免疫学，以加强我们新的疫苗试验中心，第二个是慢性感染/炎症诱导的癌症，以拓宽我们对慢性感染性疾病影响的思考。核心将继续在基因组技术/生物信息学和蛋白质组学，增加了一个新的BSL 3设施的核心，以适应VCIID研究人员希望研究BSL 3代理日益增长的需求。此外，在这一领域，我们将形成一个独特的合作伙伴关系之间的VCIID，UVM和卫生的佛蒙特州部门，其中国家将建立卫生实验室建设的新部门在UVM校园连接到我们的研究大楼包含BSL 3设施。这将为扩大的联合BSL 3设施提供空间，以包括动物和选择剂的使用。这些努力将使我们在新的POI和U19类别赠款方面具有竞争力。

This application proposes the Phase II COBRE continuation of the Vermont Center for Immunology and Infectious Diseases (VCIID) at the University of Vermont (UVM). During the Phase I COBRE period we created a multidisciplinary group of scientists and clinicians undertaking collaborative research in microbial pathogenesis and the immune response to infections. The keystone of Phase I was to achieve scientific excellence while building a critical mass of investigators in a vibrant and rigorous atmosphere. A significant component of this was the mentoring of 5 original junior faculty, all of whom obtained extramural funding, had numerous publications and awards, and 4 of 5 have been promoted. We also recruited 5 additional junior faculty in the final two years of Phase I. Already 4 of these 5 new faculty have obtained some extramural funding. In addition, the VCIID-COBRE provided support for cores in Genome Technologies/Bioinformatics, Proteomics, a seminar series of outside experts, a weekly Research-in- Progress forum, retreats, pilot project funding, and workshops on scientific issues, grant writing, and career development. As a result of these programs the VCIID grew during Phase I from 9 founding faculty to 21 faculty in 8 departments in 4 colleges, with 213 publications (49 from junior faculty), $47,694,003 in funding, without the COBRE ($8,818,374 from junior faculty), and recognition by the UVM College of Medicine as one of the five Centers of Excellence. During Phase II we will continue several of the above successful programs but modify them toward directing the faculty toward becoming a highly interactive group in a mature Center with collaborative grants and sustainability. The new 5 junior faculty will continue their projects for 1-4 additional years. Two senior faculty we be recruited to fill gaps in our intellectual repertoire, one in mucosal immunology to enhance our new Vaccine Trials Center, and the second in chronic infection/inflammation-induced cancer to broaden our thinking to the implications of chronic infectious conditions. Cores will be continued in Genome Technologies/Bioinformatics and Proteomics, with the addition of a new BSL3 facility core to accommodate the growing needs of VCIID investigators desiring to study BSL3 agents. Also in this area, we will form a unique partnership among the VCIID, UVM, and the Vermont Department of Health in which the State will build a new Department of Health laboratory building on the UVM campus attached to our research building containing the BSL3 facility. This will provide space for an expanded joint BSL3 facility to include animal and select agent use. These endeavors will position us to be competitive for new POI and U19 category grants.